Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: To evaluate the efficacy and safety of adalimumab (ADA) in moderately to severely active ulcerative colitis (UC) patients who are unresponsive to traditional therapy. Methods: Electronic databases, including the PubMed, Embase, and Cochrane databases, were searched to April 20, 2014. UC-related randomized controlled trials (RCTs) that compared ADA with placebo were eligible. Review Manager 5.1 was used for data analysis. Results: This meta-analysis included three RCTs. ADA was considerably more effective compared with a placebo, and it increased the ratio of patients with clinical remission, clinical responses, mucosal healing and inflammatory bowel disease questionnaire responses in the induction and maintenance phases (p<0.05), as well as patients with steroid-free remission (p<0.05) during the maintenance phase. Clinical remission was achieved in a greater number of UC cases in the ADA 160/80/40 mg groups (0/2/4 week, every other week) compared with the placebo group at week 8 (p=0.006) and week 52 (p=0.0002), whereas the week 8 clinical remission rate was equivalent between the ADA 80/40 mg groups and the placebo group. Among the patients who received immunomodulators (IMM) at baseline, ADA was superior to the placebo in terms of inducing clinical remission (p=0.01). Between-group differences were not observed in terms of serious adverse events (p=0.61). Conclusions: ADA, particularly at doses of 160/80/40 mg (0/2/4 week, every other week), is effective and safe in patients with moderate-to-severe UC who are unresponsive to traditional treatment. Concomitant IMM therapy may improve the short-term therapeutic efficacy of ADA.
Abstract
Background/Aims: To evaluate the efficacy and safety of adalimumab (ADA) in moderately to severely active ulcerative colitis (UC) patients who are unresponsive to traditional therapy. Methods: Electronic databases, including the PubMed, Embase, and Cochrane databases, were searched to April 20, 2014. UC-related randomized controlled trials (RCTs) that compared ADA with placebo were eligible. Review Manager 5.1 was used for data analysis. Results: This meta-analysis included three RCTs. ADA was considerably more effective compared with a placebo, and it increased the ratio of patients with clinical remission, clinical responses, mucosal healing and inflammatory bowel disease questionnaire responses in the induction and maintenance phases (p<0.05), as well as patients with steroid-free remission (p<0.05) during the maintenance phase. Clinical remission was achieved in a greater number of UC cases in the ADA 160/80/40 mg groups (0/2/4 week, every other week) compared with the placebo group at week 8 (p=0.006) and week 52 (p=0.0002), whereas the week 8 clinical remission rate was equivalent between the ADA 80/40 mg groups and the placebo group. Among the patients who received immunomodulators (IMM) at baseline, ADA was superior to the placebo in terms of inducing clinical remission (p=0.01). Between-group differences were not observed in terms of serious adverse events (p=0.61). Conclusions: ADA, particularly at doses of 160/80/40 mg (0/2/4 week, every other week), is effective and safe in patients with moderate-to-severe UC who are unresponsive to traditional treatment. Concomitant IMM therapy may improve the short-term therapeutic efficacy of ADA.
참고문헌 (31)
- Solberg IC, "Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)", Scand J Gastroenterol, 44, pp.431~440 (2009)
- Feuerstein JD, "Ulcerative colitis: epidemiology, diagnosis, and management", Mayo Clin Proc, 89, pp.1553~1563 (2014)
- Rubin DT, "The impact of ulcerative colitis on patients’ lives compared to other chronic diseases:a patient survey", Dig Dis Sci, 55, pp.1044~1052 (2010)
- Afif W, "Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab", Inflamm Bowel Dis, 15, pp.1302~1307 (2009)
- Barreiro-de Acosta M, "Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years", World J Gastroenterol, 15, pp.3814~3816 (2009)
- Peyrin-Biroulet L, "Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study", World J Gastroenterol, 13, pp.2328~2332 (2007)
- Reinisch W, "Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial", Gut, 60, pp.780~787 (2011)
- Sandborn WJ, "Adalimumab induces and maintains clinical remission in patients with moderateto-severe ulcerative colitis", Gastroenterology, 142(e3), pp.257~265 (2012)
- Suzuki Y, "Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis", J Gastroenterol, 49, pp.283~294 (2014)
- "GIDAC briefing document" (2012)[URL]
- Dignass A, "Second European evidencebased consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis", J Crohns Colitis, 6, pp.965~990 (2012)
- Guyatt G, "A new measure of health status for clinical trials in inflammatory bowel disease", Gastroenterology, 96, pp.804~810 (1989)
- Irvine EJ, "Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease: Canadian Crohn’s Relapse Prevention Trial Study Group", Gastroenterology, 106, pp.287~296 (1994)
- Tarsilla M, "Cochrane handbook for systematic reviews of interventions", J Multidiscip Eval, 6, pp.142~148 (2010)
- Jadad AR, "Assessing the quality of reports of randomized clinical trials: is blinding necessary?", Control Clin Trials, 17, pp.1~12 (1996)
- Oussalah A, "Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience", Aliment Pharmacol Ther, 28, pp.966~972 (2008)
- Gies N, "Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort", Aliment Pharmacol Ther, 32, pp.522~528 (2010)
- Feagan BG, "Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis", Gastroenterology, 146(e3), pp.110~118 (2014)
- Sandborn WJ, "One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2", Aliment Pharmacol Ther, 37, pp.204~213 (2013)
- Vogelaar L, "The impact of biologics on health-related quality of life in patients with inflammatory bowel disease", Clin Exp Gastroenterol, 2, pp.101~109 (2009)
- Reinisch W, "52-Week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and", or immunosuppressants, 2013, pp.19, 1700~1709
- Lv R, "Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis", PLoS One, 9, pp.e86692~ (2014)
- 박성철, "Current and Emerging Biologics for Ulcerative Colitis", Gut and Liver, 9(1), pp.18~27 (2015), 거트앤리버 발행위원회
- Chen-Wang Chang, "Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn’s Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study", Intestinal research, 12(4), pp.287~292 (2014), 대한장연구학회
- Armuzzi A, "Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab", Int J Immunopathol Pharmacol, 27(1), pp.11~32 (2014)
- Blandizzi C, "The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases", Int J Immunopathol Pharmacol, 27(1), pp.1~10 (2014)
- Lapadula G, "Adalimumab in the treatment of immune-mediated diseases", Int J Immunopathol Pharmacol, 27(1), pp.33~48 (2014)
- Nielsen OH, "Tumor necrosis factor inhibitors for inflammatory bowel disease", N Engl J Med, 369, pp.754~762 (2013)
- Colombel JF, "Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial", Gastroenterology, 132, pp.52~65 (2007)
- D’Haens GR, "The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization:when to start, when to stop, which drug to choose, and how to predict response?", Am J Gastroenterol, 106, pp.199~212 (2011)
- Colombel JF, "Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3", Am J Gastroenterol, 109, pp.1771~1780 (2014)